… with LY-CoV555 protected the upper and lower respiratory tracts of nonhuman primates from
… Together, these data support the clinical use of LY-CoV555 for treating patients with COVID-…

… (10) LY-CoV555 was observed to bind to an epitope … (5, 20, 21) Based on the crystal structure,
the LY-CoV555 epitope … of LY-CoV555 Fab complexes in which the LY-CoV555 Fab was …

… of LY-CoV555 and its passive protection against SARS-CoV-2 in nonhuman primates
has … The use of these doses was supported by safety data from a phase 1 trial of LY-CoV555 …

… In a non-human primate model of SARS-CoV-2 infection, prophylactic AZD7442 administration
prevented infection, while therapeutic administration accelerated virus clearance from …

… The antibody combination protected nonhuman primates from infection with SARS-CoV-2
when administered prophylactically or therapeutically. The antibodies were also resistant to all …

… The provisional analysis of LY-CoV555 phase 2 clinical trial (NCT04427501) showed …
to LY-CoV555 [71]. However, administration of LY-CoV555 combined with another mAb, LY-…

… On 9 November 2020, the US Food and Drug Administration issued an emergency use
authorization for bamlanivimab (LY3819253/LY-CoV555) for the treatment of mild-to-moderate …

… odds ratio of a better outcome with LY-CoV555 than with placebo using proportional-odds …
the primary safety analysis, which compared LY-CoV555 with placebo with respect to the …

… LY-CoV555, K417N/T escapes LY-CoV016). In addition, the L452R mutation in the B.1.429
lineage escapes LY-CoV555… that escape the combined LY-CoV555+LY-CoV016 cocktail. …

… LY-CoV555 monotherapy or combination therapy with LY-CoV016 showed no difference in
viral load between LY-CoV555 … Immunization of nonhuman primates with 10 or 100 µg of the …